Layoffs in the biopharma sector surged 32% year-over-year in the first half of 2025, marking an all-time high for monthly reduction-in-force rounds, with 29 reported in May alone. Several biotechs have undergone multiple layoff rounds and closures amid financial and development setbacks. In parallel, biopharma financing declined 59% compared to 2024, totaling $28.7 billion in H1 2025, reflecting a challenging funding environment. Some companies have garnered significant Series A funds despite leadership gaps, while others pursue acquisition or restructuring strategies to extend runways amid intensified market pressures.